Site Editor

Rebecca Olin, MD, MS

Advertisement
Advertisement

Dose-Escalation Trial to Focus on Anti-CD117 Antibody-Drug Conjugate in AML

By: Kayci Reyer
Posted: Wednesday, August 10, 2022

An ongoing phase I/II trial, the details of which were presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting (Abstract TPS3156), will evaluate the safety and clinical efficacy of MGTA-117, a novel ant-CD117 antibody-drug conjugate, in the treatment of patients with AML or myelodysplasia with excess blasts. MGTA-117 is a potential conditioning agent for hematopoietic stem cell transplantation candidates; the study authors recognize the possibility that patients may undergo transplantation at least 29 days after receiving MGTA-117.

“Human hematopoietic stem cells and AML tumor cells express high levels of CD117, and MGTA-117 potently depletes these target cells, with [a half-maximal inhibitory concentration] of < 10 pM in vitro,” noted Andrew S. Artz, MD, of City of Hope, Duarte, California, and colleagues. “MGTA-117 has demonstrated in vitro and in vivo stability, confirming its characterization as a highly potent and selective agent.”

The multicenter dose-escalation study will enroll patients between the ages of 18 and 75 who have been diagnosed with CD117-positive relapsed/refractory AML or myelodysplasia with excess blasts and at least 5% marrow myeloblasts with an Eastern Cooperative Oncology Group performance status of up to 2. Patients will participate in a dose-escalation process to meet the study’s primary endpoint of determining the minimum safe and effective dose of MGTA-117. Efficacy will be measured by CD117 receptor occupancy in circulating leukemic blasts following dose administration.

A 21-day observation window for dose-limiting toxicities will be established. Reticulocyte, neutrophil, and platelet counts in peripheral blood will be monitored and measured against baseline counts from leukemic blasts or stem/progenitor cells in peripheral blood and/or bone marrow.

Disclosure: For full disclosures of the study authors, visit coi.asco.org.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.